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Prenatally administered rosiglitazone (RGZ) is effective in enhancing lung maturity; however, its long-term safety remains
unknown. This study aimed to determine the effects of prenatally administered RGZ on the metabolic phenotype of adult rats.
Methods. Pregnant Sprague-Dawley rat dams were administered either placebo or RGZ at embryonic days 18 and 19. Between 12
and 20 weeks of age, the rats underwent glucose and insulin tolerance tests and de novo fatty acid synthesis assays. The lungs, liver,
skeletal muscle, and fat tissue were processed by Western hybridization for peroxisome proliferator-activated receptor (PPAR)γ,
adipose differentiation-related protein (ADRP), and surfactant proteins B (SPB) and C (SPC). Plasma was assayed for triglycerides,
cholesterol, insulin, glucagon, and troponin-I levels. Lungs were also morphometrically analyzed. Results. Insulin and glucose
challenges, de novo fatty acid synthesis, and all serum assays revealed no differences among all groups. Western hybridization
for PPARγ, ADRP, SPB, and SPC in lung, liver, muscle, and fat tissue showed equal levels. Histologic analyses showed a similar
number of alveoli and septal thickness in all experimental groups. Conclusions. When administered prenatally, RGZ does not affect
long-term fetal programming and may be safe for enhancing fetal lung maturation.
1. Introduction
Peroxisome proliferator-activated receptor (PPAR)γ is a
ligand-activated transcription factor that belongs to the
superfamily of nuclear hormone receptors [1]. Several
studies have evaluated the role of PPARγ in lung maturation,
demonstrating its critical significance in stimulating the
alveolar epithelial-mesenchymal paracrine signaling pathway
[2–5]. Recent studies have also shown that PPARγ agonists
such as rosiglitazone (RGZ) significantly enhance lung
maturation when administered antenatally. Its efficacy in
enhancing pulmonary maturation and neonatal and long-
term safety following postnatal administration has also been
demonstrated recently [5, 6]. In those studies, lack of any
significant impact on the neonatal and long-term metabolic
profile of the exposed offspring was demonstrated [5, 6].
However, data on the long-term effects of RGZ are sparse,
and to date no study has examined the effects of RGZ on the
metabolic profile of adult rats when administered prenatally.
Despite the morbidity and mortality associated with
bronchopulmonary dysplasia (BPD), there are no effective
pharmacologic preventive or therapeutic options available.
Antenatal steroid administration is the standard of care
for augmenting pulmonary maturity in the presence of
imminent premature labor [7, 8]. However, steroids have
both limitations and concerning side effects [9]. Given that
antenatal PPARγ administration enhances lung maturation
and may be an alternative to antenatal steroids, it is critically
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important to determine its long-term safety before this
treatment modality can be considered for human use.
Therefore, we wanted to determine the adult metabolic
profile and lung structure of adult rats exposed to RGZ
antenatally and compare these to the metabolic profile and
lung structure of rats exposed to dexamethasone antenatally.
To accomplish this, we utilized a previously described animal
model to study the effects of prenatally administered RGZ on
markers of lung maturation and the metabolic programming
[5, 6].
Based on previous studies, we hypothesized that a PPARγ
agonist given prenatally to accelerate lung development
would not significantly alter the metabolic profile or phe-
notype [10]. Given the known effects of PPARγ agonists on
the regulation of insulin and lipid metabolism, we examined
the effects of antenatal RGZ on the basic metabolic profile by
measuring body weight, glucose and insulin tolerance tests,
de novo fatty acid synthesis, plasma troponin-I, cholesterol,
triglycerides, insulin, and glucagon levels [11–13]. Lung
maturation in adult animals was assessed by examining the
expression of surfactant proteins B (SPB) and C (SPC),
PPARγ and ADRP, key alveolar epithelial, and mesenchymal
molecular markers [5, 14]. Lung morphometry was assessed
by determining radial alveolar counts and septal thickness.
2. Methods
Pathogen-free, time-mated, first-time pregnant Sprague-
Dawley rats (285–295 g) were obtained at day 16 of gestation
(day 21= term). They were allowed food and water ad
libitum in a humidity- and temperature-controlled room on
a 12-h : 12-h-light : dark cycle. Rats were assigned to each of
the 4 treatment groups, receiving either diluent, (cottonseed
oil), 0.3mg/kg of RGZ (Cayman Chemicals, Ann Arbor,
MI), 3mg/kg of RGZ, or 0.25mg/kg of dexamethasone
(Dexa) intraperitoneally (i.p.). The diluent, RGZ or Dexa,
was administered using a microsyringe in 100 μL volumes
injected i.p. once daily on gestational days 18 and 19, 24
hours apart, for a total of two doses each. On day 22 of
pregnancy, the dams delivered spontaneously. A total of 33
pups from 4 litters (for each study group), with a minimum
of 2 males and 3 females in each group were studied.
Pups were breast-fed ad libitum and then weaned to rat
chow on postnatal day 21. Glucose tolerance and insulin
tolerance tests were performed at 12 weeks of age. To perform
these studies, either glucose or insulin was administered
after an overnight fast. At 20 weeks, the left lungs were
collected and flash-frozen for later Western hybridization
to determine the expression of PPARγ, ADRP, SPB, and
SPC. Right lungs were inflated with saline at a pressure
of 20 cm H2O, after which the trachea was immediately
ligated to maintain inflation. Subsequently, the lungs were
stored in 30% dextrose for 2 weeks after which they were
embedded in paraffin for further sectioning, H&E staining,
and light microscopy. Liver, muscle, and perinephric fat were
also collected and flash-frozen to determine the effects of
prenatal RGZ on the expression of PPARγ and ADRP, a
downstream target of PPARγ. Peripheral blood was collected
and stored at −80◦C for later determination of cholesterol,
triglyceride, glucagon, insulin, cardiac troponin, and fatty
acids. In a subset of animals (n = 6 for each group; 3M : 3F),
at 19 weeks de novo fatty acid synthesis and incorporation
into tissues were analyzed by deuterium (D2O) labeling and
mass spectrometry, as previously described [15]. Briefly,
animals received deuterated water (99.9%) prepared in
normal saline in an amount equal to ∼4% of body weight
and administered intraperitoneally and then were given
free access to drinking water containing 6% D2O for 7
days. At the end of the experimental period (∼20 weeks
of age), the animals were sacrificed using 0.1 mL euthasol
(= 39mg pentobarbital sodium, Virbac AH, Ft. Worth, TX)
per rat. All animal procedures were performed following
the guidelines of the National Institutes of Health for the
care and use of laboratory animals and approved by the Los
Angeles Biomedical Research Institute, Animal Care and Use
Committee.
2.1. Western Blot Analysis. Western analysis was performed
as described previously [5]. The primary antibodies used
included SPB, SPC (1 : 500, Santa Cruz Biotechnology Inc.,
Santa Cruz, CA), PPARγ (1 : 2000, Alexis Biochemicals,
San Diego, CA), and ADRP (1 : 500, Santa Cruz Biotech-
nology Inc., Santa Cruz, CA). The blots were subse-
quently stripped and reprobed with anti-GAPDH antibody
(1 : 10,000, Chemicon, Temecula, CA), and the protein values
were normalized to the amount of GAPDH as an internal
control.
2.2. Glucose Tolerance Test and Insulin Tolerance Test.
Either glucose (1 g/kg body wt, intraperitoneal) or insulin
(1 unit/kg, subcutaneous) was administered after an
overnight fast. Serum glucose levels were assayed at different
time points (0, 15, 30, 60, 120, and 180 minutes) using
a glucometer (Home Diagnostics, Fort Lauderdale, FL),
according to the manufacturer’s protocol.
2.3. Cholesterol and Triglyceride Assays. Cholesterol and
triglyceride levels were determined using the RAICHEM kit
(Cliniqa Corporation, SanMarcos, CA, with a dynamic range
of 0–600mg/dl, an intra-assay coefficient of variation of
1.7%), and the Cayman kit (Caymen Chemical Company,
Ann Arbor, MI, dynamic range of 0–200mg/dl, and intra-
assay coefficient of variation of 1.34%), respectively, follow-
ing the manufacturer’s protocol.
2.4. Plasma Insulin and Glucagon. Plasma insulin was mea-
sured using an ELISA kit (detection limit of 0.2 ng/mL
and 100% specificity) and glucagon was measured via an
RIA kit (detection limit of 20 pg/mL and cross-reactivity
with oxyntomodulin :<0.1%) purchased from Linco (Linco
Research, St. Charles, MO).
2.5. Measurement of Plasma Cardiac Troponin-I Levels.
Determination of cardiac troponin-I levels was done based
on a rat cardiac Troponin-I ELISA kit as per the manu-
facturer’s protocol (Cat. no. 2010-2-HSP, Life Diagnostics,
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Figure 1: Effect of RGZ on postnatal weight gain. RGZ was admin-
istered prenatally at doses of 0.3mg/kg and 3mg/kg i.p. ×2 doses.
Another group was treated prenatally with i.p. dexamethasone
(Dexa, 0.25mg/kg) × 2 doses. Weight was recorded every 2 weeks
starting at week 4 until week 14 and on the day of sacrifice. There
were no significant differences between study groups through out
the observation period.
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Figure 2: Effect of RGZ on glucose tolerance test (GTT). At 12
weeks of age, glucose was administered at 1 g/kg body weight i.p.
after an overnight fast. Glucose was assayed at time = 0 (baseline),
15, 30, 60, 120, and 180 minutes following glucose administration.
There were no significant differences (P > 0.05) in timed serum
glucose values in the treated groups compared with controls during
the GTT.
West Chester, PA) (detection limit of 0.156 ng/mL and 100%
specificity).
2.6. Fatty Acid Analysis. De novo fatty acid synthesis was ana-
lyzed by deuterium labeling, followed by mass spectrometry,
as previously described [5, 15].
2.7. Histologic Analysis. Lung morphometry was performed
following previously described methods [10].
2.8. Statistical Analysis. Analysis of variance and two-tailed
Student’s t-test with Bonferroni correction for multiple
comparisons were used to analyze the experimental data.
P values < 0.05 were considered to be statistically significant.
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Figure 3: Effect of RGZ on insulin tolerance test (ITT). At 12
weeks of age, insulin was administered at 1 unit/kg body weight
subcutaneously after an overnight fast. Glucose was assayed at
time = 0 (baseline), 15, 30, 60, 120, and 180 minutes following
insulin administration. There were no significant differences in
serum glucose values between the treated and control groups during
any of the time points of the ITT (P > 0.05).
3. Results
3.1. Effect of RGZ on Body Weight. A total of 33 pups
(8-9/group) were studied in each group. There were no
significant differences in birth weight of pups from each
experimental group. Body weight was determined every 2
weeks as an overall measure of growth and metabolism
starting on day 30 of life until week 14 and at sacrifice. We
found no significant differences (P > 0.05) in body weight
among the treatment groups at all time-points examined
(Figure 1).
3.2. Effect of RGZ on Glucose and Insulin Tolerance. Glucose
and insulin tolerance tests showed no significant differences
in glucose values among the different groups at all time-
points examined (Figures 2 and 3).
3.3. Effect of RGZ on Insulin, Glucagon, and Cardiac Tro-
ponin Levels. Table 1 shows that there were no significant
differences in insulin, glucagon, or cardiac troponin-I levels
among any of the groups, (P > 0.05 for all).
3.4. Effect of RGZ on Blood Cholesterol and Triglyceride Levels.
Table 1 shows no significant differences in plasma cholesterol
and triglyceride levels in the control group versus the RGZ or
Dexa-treated group, (P > 0.05 for all).
3.5. Effect of RGZ on Fatty Acid Synthesis. Analyses of de
novo fatty acid synthesis and their incorporation into tissues
at 19 weeks showed that the fraction of de novo synthesized
palmitate molecules in the RGZ- and Dexa-treated groups
were comparable to the control group (Table 2).
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Table 1: Insulin, glucagon, lipids, and troponin measurements. Plasma samples taken at 20 weeks for metabolic analyses showed there were
no significant differences (P > 0.05) in insulin, glucagon, lipids, and troponin measurements in RGZ- and dexamethasone-treated groups
compared with controls. Values are mean ± SD. N = 24 (6 in each group).
Treatment group Insulin (ng/mL) Glucagon (pg/mL) Triglycerides (mg/dL) Cholesterol (mg/dL) Troponin (ng/mL)
Control 2.3± 1.7 217.3± 12 33.2± 15 94.4± 15 0.18± 0.18
RGZ 0.3mg/kg 2.6± 1.4 190.6± 6 35.6± 6 105.1± 15 0.16± 0.23
RGZ 3mg/kg 2.7± 0.9 208.2± 23 32.5± 23 108.9± 14 0.10± 0.08
Dexamethasone 0.25mg/kg 2.3± 1.4 207.8± 13 30.3± 13 95.8± 21 0.13± 0.13
Table 2: Effect of RGZ on fatty acid synthesis. At 19 weeks,
the fraction of de novo lipogenesis and incorporation into the
tissues were analyzed by deuterium labeling andmass spectrometry.
There were no significant differences (P > 0.05) in the fraction
of de novo synthesis of palmitate molecules in the RGZ- and
dexamethasone-treated groups compared with the controls. m1 =
fraction of isotopomer molecules with one deuterium substitution,
m2 = fraction of isotopomer molecules with two deuterium atoms.
N = 24 (6 in each group).
Group m2/m1
Deuterium
enrichment
(%)
Fraction of
new palmitate
molecules
Control 0.36 0.04 0.28
RGZ 0.3mg/kg 0.41 0.04 0.28
RGZ 3mg/kg 0.35 0.04 0.25
Dexamethasone 0.25mg/kg 0.37 0.04 0.30
3.6. Effect of RGZ on Alveolar Differentiation. Western blot
analysis for SPB, SPC, PPARγ, and ADRP on protein lysates
from whole lung samples from different groups showed
that when compared to control, Dexa- and RGZ-treated
groups had no significant effect on the expression of all the
molecular markers probed (P > 0.05 for all, Figure 4).
3.7. Effect of RGZ on PPARγ and ADRP Expression in
Liver, Muscle, and Perinephric Fat. Figure 5 shows Western
Blot results for the extrapulmonary PPARγ- and ADRP-
expressing tissues (liver, muscle, and perinephric fat) exam-
ined. There were no significant differences in PPARγ and
ADRP protein levels among the different treatment groups
when compared with controls (P > 0.05 for all).
3.8. Lung Histology. Morphometric analysis showed no sig-
nificant differences in septal thickness and alveolar count
between the control, Dexa, and RGZ-treated groups (P >
0.05, Figure 6).
4. Discussion
In view of the increasing survival of extremely low birth
weight infants and the accompanying increased prevalence
of BPD, it is imperative that we find optimal preventive and
therapeutic interventions to decrease the morbidities and
mortality associated with this condition [16]. At present, the
standard of care to augment lung maturity during immi-
nent premature delivery is antenatal steroid administration;
however, evidence suggests steroids may increase the risk for
significant adverse effects like altered neuronal development
[17]. Despite the necessity to find an optimal treatment
for lung immaturity, extensive research in the field has not
succeeded in finding such an alternative to antenatal steroids.
In the last decade, the possibility of using PPARγ agonists to
enhance lung maturation and promote lung injury repair has
been explored [1–3]. In addition, our laboratory has shown
that in the developing lung PPARγ agonists can prevent lung
injury induced by infection, nicotine, or hyperoxia [18, 19].
Similarly, a recent study by Garg et al. has provided evidence
that early postnatal administration of PPARγ agonists can
reverse the effects of growth restriction [20].
Regardless of its evident efficacy, the long-term safety
of prenatally administered PPARγ agonists is unknown.
Our present study is the first to examine the long-lasting
molecular effects of prenatally administered RGZ, a potent
PPARγ agonist. Our results demonstrate that all of the
metabolic parameters examined did not change, and RGZ
did not alter the adult phenotype of our experimental groups
compared with controls. Given RGZ’s known effects on
insulin and fat metabolism, we determined the body weight
patterns across all study groups and observed no significant
differences in growth rate and adult weight at 20 weeks of age
[12, 19]. Since PPARγ activation regulates the transcription
of insulin-responsive genes involved in the metabolism of
glucose, we also studied the effects of RGZ on glucose
and insulin tolerance as well as glucagon and insulin levels
in adults following prenatal RGZ administration [21]. We
found that RGZ did not affect either the glucose or insulin
tolerance tests, nor the serum insulin or glucagon levels in
any of the experimental groups.
Given that PPARγ-related genes are involved in the
regulation of lipid metabolism and have effects on the lipid
profile, we also determined serum cholesterol and triglyc-
eride levels, as well as de novo fatty acid synthesis, among
the experimental groups and found no alterations in either
serum triglyceride or cholesterol levels when compared to
non-treated animals [11]. Results of mass spectrometric
analyses did not show alterations in the rate of de novo fatty
acid synthesis in the experimental groups.
Rosiglitazone is widely used in the adult population
for the treatment of hyperglycemia in diabetes [21, 22].
Recent reports have associated RGZ at a dose of 4mg twice
daily for a period of 20 weeks with an elevated risk of
cardiovascular events in this population [23]. We measured
cardiac troponin due to its well-established validity as a
marker for cardiac injury and to allow for comparison with
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Figure 4: Effect of RGZ on SPB, SPC, PPARγ, and ADRP expression in lung. Utilizing Western blot, SPB, SPC, PPARγ, and ADRP levels
were determined in lung lysates. There were no significant differences (P > 0.05) in protein levels of SPB (a), SPC (b), PPARγ (c), or ADRP
(d) in lung, in the RGZ- and dexamethasone- (Dexa-) treated groups compared with the controls. Representative Western blots and the
corresponding density histograms are shown (n = 4 in each group).
previous data on rat cardiac function studies [24]. Our study
did not reflect any differences in troponin-I levels among the
study groups. In contrast to the human data, the absence of
cardiotoxicity of RGZ is probably due to much shorter and
lower doses used in our animal study compared to much
greater exposure in adults (2 doses in our study versus 280
doses in the adult studies).
In addition, we measured the effect of antenatally
administered RGZ on the expression of SBP, SPC, PPARγ,
and ADRP (the downstream target of PPARγ) in the lung,
and in selected extrapulmonary PPARγ-expressing tissues
such as the liver, adipose tissue, and muscle. Our results
show that when compared to controls, there were no
significant differences in the expression of SPB, SPC, PPARγ,
or ADRP in either the pulmonary or extra-pulmonary tissues
examined. Lastly, morphologic studies did not show any
differences in the septal thickness and number of alveoli
between the experimental and control groups.
In summary, long-term followup after prenatal admin-
istration of RGZ showed no effects on body weight, insulin
and glucagon tolerance tests as well as on insulin, glucagon,
triglyceride, cholesterol, or troponin-I levels. In addition,
RGZ did not have any effects on fatty acid synthesis or lung
morphology, suggesting absence of any long-term metabolic
or pulmonary effects following antenatal exposure.
Among the various thiazolidinediones, RGZ was selected
for this study based on extensive clinical experience of others
and our studies on its role in perinatal lung maturation
[5, 25–27]. The results of this study should be interpreted
with caution since given the small sample size, the possibility
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Figure 5: Effect of RGZ on PPARγ and ADRP expression in liver, skeletal muscle, and perinephric fat. UtilizingWestern blot assay, PPARγ (a)
and ADRP (b) protein levels were examined in the whole tissue lysates of liver, skeletal muscle, and perinephric fat. There were no significant
differences (P > 0.05) in the protein levels of PPARγ and ADRP in the liver, skeletal muscle, or perinephric fat, normalized to GAPDH, in
the treated groups compared with the control. Representative Western blots and the corresponding density histograms are shown (n = 4 in
each group).
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Figure 6: H&E staining of lung samples showed no significant differences in the alveolar number and septal thickness at 20 weeks, between
control and treated groups. Light microscopy images of the sections at 20x magnification are shown. P > 0.05 for all groups and n = 4 in
each group.
of a type II error canot be ruled out. However, the promising
benefits of thiazolidinediones at the doses used in our studies
and the favorable long-term results in the present study
strengthen the argument for the use of PPARγ agonists as an
effective and safe alternative for the prevention of BPD.
5. Conclusions
RGZ is an effective intervention in the enhancement of lung
maturity and the promotion of lung injury repair. Long-
term followup of antenatally treated subjects in our study
did not show any changes in their metabolic profile or in
their phenotype, suggesting that PPARγ agonists are a safe
alternative for the prevention and treatment of BPD. Though
human studies have shown increased cardiovascular risk
associated with RGZ, such adverse effects were not seen in
this study, probably due to very different dosing regimens
[23, 28]. RGZ is a prototype for the thiazolidinedione group
of drugs and our results possibly demonstrate a beneficial
class effect suggesting the need for pharmacokinetic and
pharmacodynamic studies in humans with the goal of
developing this class of drugs as an effective and safe
alternative to enhance fetal lung maturation.
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